Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG)

Annals of Oncology

Volumn 17, Issue 2, 2006, Pages 276-280

  Krege, Susanne ^a   Boergermann, C ^a   Baschek, R ^a   Hinke, A ^b   Pottek, T ^c   Kliesch, S ^d   Dieckmann, K P ^e   Albers, P ^f   Knutzen, B ^g   Weinknecht, S ^h   Schmoll, H J ⁱ   Beyer, J ^j   Ruebben, H ^a  

^a Department of Urology   (Germany)

^b Wissenschaftlicher Service Pharma   (Germany)

^c Bundeswehrkrankenhaus Hamburg   (Germany)

^d INST OF REPRO MED OF THE UNIV   (Germany)

^e ALBERTINEN KRANKENHAUS   (Germany)

^f KLINIKUM KASSEL   (Germany)

^g Klinikum der Stadt Schwenningen   (Germany)

^h KLINIKEN ESSEN MITTE   (Germany)

ⁱ Department of Medical Oncology   (Germany)

^j PHILIPPS UNIVERSITY MARBURG   (Germany)

more..

Author keywords

Carboplatin; Chemotherapy; Testicular seminoma stage IIA B

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CREATININE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GERMANY; HEMATURIA; HUMAN; INFECTION; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEMINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMATITIS; TESTIS CANCER; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; SEMINOMA; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS;

EID: 31544447508     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj039     Document Type: Article

References (20)

1. Warde P, Gospodarowicz M, Panzarella T et al. Management of stage II seminoma. J Clin Oncol 1998; 16: 290-294.
2. Classen J, Souchon R, Hehr T, Bamberg M. Treatment of early stage testicular seminoma. J Cancer Res Clin Oncol 2001; 127: 475-481.
3. Classen J, Schmidberger H, Meisner C et al. Radiotherapy for stages IIA/ B testicular seminoma: Final report of a prospective multicenter clinical trial. J Clin Oncol 2003; 21: 1101-1106.
4. Bokemeyer C, Schmoll H.-J. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993; 11: 1703-1709.
5. Oliver RTD, Edmonds PM, Ong JYH et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: Should it be tested in a randomized trial against radiotherapy? Int J Radiation Oncology Biol Phys 1994; 29: 3-8.
6. Krege S, Kalund G, Otto T et al. Phase II study: Adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 1997; 31: 405-407.
7. Dieckmann K-P, Brüggeboes B, Pichlmeier U et al. Adjuvant treatment of clinical stage I seminoma: Is a single course of carboplatin sufficient? Urology 2000; 55: 102-106.
8. Oliver RTD, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: A randomised trial of the testis, following orchidectomy: MRC TE19/EORTC 30982. Lancet 2005; 366: 293-300.
9. Pizzocaro G, Salvioni R, Piva L et al. Cisplatin combination chemotherapy in advanced seminoma. Cancer 1986; 58: 1625-1629.
10. Horwich A, Dearnaley DP, Duchesne GM et al. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 1989; 7: 1150-1156.
11. Schmoll H-J, Harstrick A, Bokemeyer C et al. Single-agent carboplatin for advanced seminoma. Cancer 1993; 72: 237-243.
12. Horwich A, Oliver RTD, Wilkinson PM et al. A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced seminoma. Br J Cancer 2000; 83: 1623-1629.
13. Bokemeyer C, Kollmannsberger C, Stenning S et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: A pooled analysis of two randomised trials. Br J Cancer 2004; 91: 683-87.
14. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173-1180.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete Observations. J Am Statistic Assoc 1958; 53: 457-481.
16. Travis LB, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429-1439.
17. Malas S, Sur RK, Levin V et al. Toxicity in patients with testicular seminoma treated with radiotherapy. Acta Oncologica 1996; 35: 201-206.
18. Chung PWM, Gospodarowicz MK, Panzarella T et al. Stage II testicular seminoma: Patterns of recurrence and outcome of treatment. Eur Urol 2004; 45: 754-760.
19. Miller KD, Loehrer PJ, Gonin R et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 1997; 15: 1427-1431.
20. Patterson H, Norman AR, Mitra SS et al. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 2001; 59: 5-11.